IgG and Fcγ Receptors in Intestinal Immunity and Inflammation.
Frontiers in immunology
MetadataShow full item record
Castro-Dopico, T., & Clatworthy, M. (2019). IgG and Fcγ Receptors in Intestinal Immunity and Inflammation.. Frontiers in immunology, 10 805. https://doi.org/10.3389/fimmu.2019.00805
Fcγ receptors (FcγR) are cell surface glycoproteins that mediate cellular effector functions of immunoglobulin G (IgG) antibodies. Genetic variation in FcγR genes can influence susceptibility to a variety of antibody-mediated autoimmune and inflammatory disorders, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). More recently, however, genetic studies have implicated altered FcγR signalling in the pathogenesis of inflammatory bowel disease (IBD), a condition classically associated with dysregulated innate and T cell immunity. Specifically, a variant of the activating receptor, FcγRIIA, with low affinity for IgG, confers protection against the development of ulcerative colitis, a subset of IBD, leading to a re-evaluation of the role of IgG and FcγRs in gastrointestinal tract immunity, an organ system traditionally associated with IgA. In this review, we summarise our current understanding of IgG and FcγR function at this unique host-environment interface, from the pathogenesis of colitis and defence against enteropathogens, its contribution to maternal-foetal cross-talk and susceptibility to cancer. Finally, we discuss the therapeutic implications of this information, both in terms of how FcγR signalling pathways may be targeted for the treatment of IBD and how FcγR engagement may influence the efficacy of therapeutic monoclonal antibodies in IBD.
Gastrointestinal Tract, Intestinal Mucosa, Animals, Humans, Inflammatory Bowel Diseases, Disease Susceptibility, Inflammation, Immunoglobulin G, Receptors, IgG, Age Factors, Signal Transduction, Autoimmunity, Protein Binding, Disease Management, Molecular Targeted Therapy, Biomarkers
Department of Health (via National Institute for Health Research (NIHR)) (NIHR BTRU-2014-10027)
Arthritis Research UK (21777)
Embargo Lift Date
External DOI: https://doi.org/10.3389/fimmu.2019.00805
This record's URL: https://www.repository.cam.ac.uk/handle/1810/291194
All rights reserved